ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0
Recruiting
Observational Study
Prostate Cancer
Prostate Cancer (Adenocarcinoma)
Prostate Cancer Non-Metastatic
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 90
- Sex
- Male
- Study type
- Observational
- Participants needed
- 58 (estimated)
- Sponsor
- University of Milano Bicocca · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Published clinical evidence confirms that a single dose of 24 Gy provides unprecedented long-term local control in primary and metastatic prostate cancer with safe toxicity profiles, provided that exposure of surrounding healthy tissues is critically assessed with fulfillment of strict constraints and dose distribution is accomplished using image guidance and tracking tools. In the present trial, …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histologically proven prostate adenocarcinoma;
* Intermediate and High risk disease, as per the NCCN definition;
* a PI-RADS 3-5 dominant intraprostatic lesion on multiparametric MRI (mpMRI);
* N0M0 at staging with standard techniques (Bone Scan and Abdominal CT) or (preferabl…
Contacts